China Clears IASO208 for Clinical Study

Company IASO Bio Event Type China IND clearance Modality In vivo CAR T (lentiviral) Asset IASO208 Target CD20 Disease Area Relapsed or refractory B-cell non-Hodgkin lymphoma Summary IASO Bio disclosed November 11 that China cleared the IND for IASO208, a CD20-targeted in-vivo CAR-T program. IND…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *